Cargando…
Is There Already a Need of Reckoning on Cancer Immunotherapy?
Autores principales: | Correale, Pierpaolo, Pentimalli, Francesca, Baglio, Giovanni, Krstic-Demonacos, Marjia, Saladino, Rita Emilena, Giordano, Antonio, Mutti, Luciano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033763/ https://www.ncbi.nlm.nih.gov/pubmed/33841155 http://dx.doi.org/10.3389/fphar.2021.638279 |
Ejemplares similares
-
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy
por: Correale, Pierpaolo, et al.
Publicado: (2020) -
Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
por: Mutti, Luciano, et al.
Publicado: (2020) -
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022) -
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
por: Pentimalli, Francesca, et al.
Publicado: (2023) -
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)